The abstract is read at the publisher; the summary is JClub's.
EMB-01 given weekly at 1,600 mg showed a confirmed objective response rate of 12.5% in 48 heavily pretreated metastatic colorectal cancer patients.
- Why it matters: Heavily pretreated mCRC has limited options, and new targeted therapies are needed to improve antitumor activity while maintaining manageable safety.
- What they did: In a Phase Ib/II open-label multicenter study (NCT05176665), EMB-01 was administered intravenously weekly, with safety assessed in Phase Ib and antitumor activity in Phase II.
- The result: All 52 patients had treatment-emergent adverse events and 63.5% had Grade ≥3 treatment-related adverse events; in the evaluable left-sided RAS/RAF wild-type subgroup naïve to late-line therapies, cORR was 20.7% with median progression-free survival of 19 weeks.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.